## 

# American Academy of Actuaries 

## GAAP Survey Results Committee on Life Insurance Financial Reporting (COLIFR)

## April 2001

The American Academy of Actuaries is the public policy organization for actuaries practicing in all specialties within the United States. A major purpose of the Academy is to act as the public information organization for the profession. The Academy is non-partisan and assists the public policy process through the presentation of clear and objective actuarial analysis. The Academy regularly prepares testimony for Congress, provides information to federal elected officials, comments on proposed federal regulations, and works closely with state officials on issues related to insurance. The Academy also develops and upholds actuarial standards of conduct, qualification and practice and the Code of Professional Conduct for all actuaries practicing in the United States.

This report was prepared by John (Jay) T. Zellner, Chair of COLIFR's GAAP Practice Notes Work Group

Committee on Life Insurance Financial Reporting
Daniel J. Kunesh, F.S.A., M.A.A.A., Chair

Thomas P. Burke, F.S.A., M.A.A.A. Errol Cramer, F.S.A., M.A.A.A. James M. Garvin, F.S.A., M.A.A.A. Vincent J. Granieri, F.S.A., M.A.A.A. Kenneth LaSorella, F.S.A., M.A.A.A. Kevin E. Palmer, F.S.A., M.A.A.A. Allan W. Ryan, F.S.A., M.A.A.A. Michael S. Smith, F.S.A., M.A.A.A. John T. Zellner, F.S.A., M.A.A.A.

William S. Cook, F.S.A., M.A.A.A. Michael L. Emerson, F.S.A., M.A.A.A. Paul S. Graham, F.S.A., M.A.A.A. Michael A. Hughes, F.S.A., M.A.A.A. John W. Morris, F.S.A., M.A.A.A. David L. Rockwell, F.S.A., M.A.A.A. David K. Sandberg, F.S.A., M.A.A.A. Roger W. Smith, F.S.A., M.A.A.A.

## Introduction

The American Academy of Actuaries' Committee on Life Financial Reporting (COLIFR) mailed out a US GAAP (Generally Accepted Accounting Practices) survey to US actuaries in 2000. The purpose of this survey was to gather statistical data to inform actuaries working on the development of US GAAP financial statements.

The survey was to provide information as to the "practices followed by companies in preparing US GAAP statements." COLIFR planned to use the survey as a source of information in the development of US GAAP practice notes on a limited number of topics and issues. This represented COLIFR's first survey on US GAAP. It is the objective of COLIFR to use the initial survey to determine a basis for the development of future surveys dealing in selected topics on US GAAP. Based on the results of the first survey, significant information was obtained on how to direct and develop future US GAAP surveys.

As a result of the very limited response to the survey ( 56 from over 1200 mailings), the credibility is reduced in trying to accomplish our original objects. Based on company size, the following numbers of companies responded:

| Size - Life Products |  |
| :--- | :---: |
| US GAAP Reserves | Number |
| $\square$ | Less than \$100 million | 4

Based on ownership structure, the following companies responded:

| Ownership Structure |  |  |
| :--- | :--- | :---: |
| Structure | Number |  |
| $\square$ | Stock Publicly Traded | 23 |
| $\square$ | Stock Privately Held | 14 |
| $\square$ | Mutual | 7 |
| $\square$ | Stock Sub of Mutual Company | 5 |
| $\square$ | Fraternal | 1 |
| $\square$ | Other | $\underline{6}$ |
| Total | $56^{*}$ |  |

*Please note that 4 companies did not have any life business and were either Annuity or A\&H companies.

US GAAP accounting has set forth requirements that are stated in general terms which lends itself to more than one interpretation and may not seem to be "on point" for a particular issue. Over time, the very
specific applications of generally accepted accounting practices evolves. This evolution is sometimes hastened by the Securities Exchange Commission (SEC) and the American Institute of Certified Public Accounts (AICPA) in their pronouncements and interpretations, which provide further guidance in the interpretations of existing and new accounting standards.

It should be recognized that the information contained in this survey provides data on practices and is not meant to define or indicate what are generally accepted US accounting standards and practices. The Actuarial Standards Board (ASB) did not promulgate this survey, nor are the results binding on any actuary.

The user of this survey should be aware that these were the practices at the time of the survey and generally accepted practices evolve over time. The user should also be aware that many of the company's answers would appear to indicate that various companies have significantly different practices in similar situations. This may not necessarily always be the case. Questions to surveys cannot always fully present all the possible variations of the facts. There may be a number of facts and situations where companies can give seemingly different answers to a given question but are, in fact, using the principles and practices in a consistent manner.

In the survey tables shown in this report, companies were asked to indicate their practice using a coded reply. The term N/A means that the question does not apply and the percent of companies falling into this category is shown. A reply of " 0 " means that the situation applies, but no action was taken by the company. In the interest of completeness and brevity, the statistics are shown including those companies indicating "not applicable." The user of these notes can easily determine the percentages of companies selecting a given answer with the "N/A" excluded.

It is not the purpose of this survey to precisely determine what is appropriate or not. It is to indicate the practices of actuaries and their relative preference for various methods. The provided selection of answers should not be construed to be a complete list of options. It is only to identify some of the various practices in the industry.

Practice Notes, as published by the American Academy of Actuaries, often take the form of a "question" followed by a discussion of alternatives, solutions, and items to consider. The survey result format provides some of these benefits as it is close to the practice note format because questions are asked and numbers or percents of companies are indicated for various indicated answers. For practical purposes the results shown are usually for "all companies combined" and "stock-publicly traded." The "stock-publicly traded" category was shown separately because it has the most credibility of any of the other ownership groups. COLIFR expects to create new surveys on specific US GAAP topics in more depth, which will enable the development of more complete US GAAP practices in the next year. The purpose of this survey is to expose the membership to a sample survey, observe the results, and to evaluate the interest of the membership in future surveys.

The questions in this survey were designed to address some of the basic principles and some of the more advanced issues in US GAAP. Because this was the first survey on US GAAP, we asked for comments on question formats and for comments on improvements in future surveys. We want to thank those of you that responded.

The number of companies replying to the questions is provided so that the user may determine their own credibility analysis of the results.

In the tables that are shown in this report, the columns headed "\% of All Companies" represent all companies in the survey regardless of products written. The tables headed "Stock Publicly Traded" represent all those companies in the report with life products in-force and excludes four companies that are exclusively either Annuity or Accident and Health (A\&H) companies.

## I. EXPENSES

1. Should a functional cost study be used to allocate expenses?
$74 \%$ of companies surveyed perform functional cost studies. There was little variation depending on size of the company.
2. How often should the functional cost study be updated as a basis for identifying and allocating deferrable acquisition and maintenance expenses?

## Deferrable Acquisition Costs

$36 \%$ of all companies update annually and $40 \%$ periodically (other than annual).

## Maintenance Costs

$45 \%$ of all companies update annually and $34 \%$ periodically (other than annual). There was little variation depending on size of the company.
3. How often should actual emerging general expense acquisition costs be identified and deferred for reporting purposes?

| Frequency | $\%$ of <br> All Companies | Very Large -2 Billion Plus <br> Life GAAP Reserves |
| :--- | :---: | :---: |
| Monthly | $31 \%$ | $38 \%$ |
| Quarterly | $35 \%$ | $50 \%$ |
| Annually | $18 \%$ | $0 \%$ |
| Not based on actual (defer expected or pricing <br> subject to not deferring more than actual) | $12 \%$ | $6 \%$ |
| Other | $4 \%$ | $6 \%$ |

## 4. How often should actual maintenance expenses be identified?

| Frequency | $\%$ of <br> All Companies | Very Large - 2 Billion Plus <br> Life GAAP Reserves |
| :--- | :---: | :---: |
| Monthly | $35 \%$ | $25 \%$ |
| Quarterly | $35 \%$ | $44 \%$ |
| Annually | $20 \%$ | $13 \%$ |
| Periodically | $2 \%$ | $6 \%$ |
| Other | $8 \%$ | $12 \%$ |

5. What percent of the following types of agent compensation and benefits are considered for capitalization as a deferred acquisition cost?

|  | Stock-Publicly Traded |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Sales conventions | $18 \%$ | $0 \%$ | $18 \%$ | $50 \%$ | $14 \%$ |
| Persistency bonuses in excess of ultimate | $17 \%$ | $0 \%$ | $4 \%$ | $40 \%$ | $39 \%$ |
| Heaped renewal commissions in excess of <br> ultimate | $17 \%$ | $0 \%$ | $4 \%$ | $66 \%$ | $13 \%$ |


|  | All Companies |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Sales conventions | $17 \%$ | $4 \%$ | $14 \%$ | $44 \%$ | $21 \%$ |
| Persistency bonuses in excess of ultimate | $17 \%$ | $0 \%$ | $4 \%$ | $36 \%$ | $43 \%$ |
| Heaped renewal commissions in excess of <br> ultimate | $12 \%$ | $0 \%$ | $2 \%$ | $67 \%$ | $19 \%$ |

6. What percent of the following types of field costs other than agent compensation is considered for capitalization as a deferred acquisition cost?

|  | Stock-Publicly Traded |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Managers' salaries and benefits | $14 \%$ | $23 \%$ | $18 \%$ | $5 \%$ | $40 \%$ |
| Clerical salaries and benefits | $18 \%$ | $18 \%$ | $18 \%$ | $5 \%$ | $41 \%$ |
| Rent, insurance related to field offices | $18 \%$ | $18 \%$ | $14 \%$ | $5 \%$ | $45 \%$ |
| Systems support to field | $25 \%$ | $20 \%$ | $10 \%$ | $0 \%$ | $45 \%$ |


|  | All Companies |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Managers' salaries and benefits | $18 \%$ | $14 \%$ | $23 \%$ | $8 \%$ | $37 \%$ |
| Clerical salaries and benefits | $22 \%$ | $12 \%$ | $23 \%$ | $4 \%$ | $39 \%$ |
| Rent, insurance related to field offices | $22 \%$ | $13 \%$ | $18 \%$ | $4 \%$ | $43 \%$ |
| Systems support to field | $37 \%$ | $18 \%$ | $10 \%$ | $2 \%$ | $33 \%$ |

## 7. What percent of the following types of home office expenses are considered for capitalization as a deferred acquisition cost?

|  | Stock-Publicly Traded |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Marketing executive salaries and benefits | $26 \%$ | $22 \%$ | $26 \%$ | $17 \%$ | $9 \%$ |
| Home office field support | $26 \%$ | $17 \%$ | $36 \%$ | $8 \%$ | $13 \%$ |
| Product specific advertising | $31 \%$ | $4 \%$ | $26 \%$ | $22 \%$ | $17 \%$ |
| General advertising | $44 \%$ | $9 \%$ | $17 \%$ | $13 \%$ | $17 \%$ |
| Senior executive salaries (president, CEO, <br> COO, etc.) | $40 \%$ | $35 \%$ | $8 \%$ | $4 \%$ | $13 \%$ |
| Support department costs (i.e., HR, etc.) | $61 \%$ | $23 \%$ | $8 \%$ | $4 \%$ | $4 \%$ |


|  | Medium Size Companies (life reserves between \$100M to \$500M) |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Marketing executive salaries and benefits | $23 \%$ | $8 \%$ | $38 \%$ | $8 \%$ | $23 \%$ |
| Home office field support | $31 \%$ | $8 \%$ | $38 \%$ | $8 \%$ | $15 \%$ |
| Product specific advertising | $15 \%$ | $0 \%$ | $0 \%$ | $54 \%$ | $31 \%$ |
| General advertising | $23 \%$ | $8 \%$ | $8 \%$ | $31 \%$ | $30 \%$ |
| Senior executive salaries (president, CEO, <br> COO, etc.) | $54 \%$ | $15 \%$ | $8 \%$ | $8 \%$ | $15 \%$ |
| Support department costs (i.e., HR, etc.) | $68 \%$ | $8 \%$ | $8 \%$ | $8 \%$ | $8 \%$ |


|  | All Companies |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Marketing executive salaries and benefits | $29 \%$ | $17 \%$ | $35 \%$ | $11 \%$ | $8 \%$ |
| Home office field support | $29 \%$ | $14 \%$ | $41 \%$ | $8 \%$ | $8 \%$ |
| Product specific advertising | $26 \%$ | $8 \%$ | $25 \%$ | $26 \%$ | $15 \%$ |
| General advertising | $44 \%$ | $8 \%$ | $19 \%$ | $17 \%$ | $12 \%$ |
| Senior executive salaries (president, CEO, <br> COO, etc.) | $53 \%$ | $25 \%$ | $10 \%$ | $4 \%$ | $8 \%$ |
| Support department costs (i.e., HR, etc.) | $57 \%$ | $25 \%$ | $10 \%$ | $4 \%$ | $4 \%$ |

## 8. What percentage of the following costs are considered maintenance expenses and are included in the GAAP benefit reserves for FAS60, the gross profit for FAS97, or the

gross margin for $F A S 120$ in cases of historical US GAAP accounting (i.e., nonpurchase situations)?

|  | Stock-Publicly Traded |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Field expenses related to servicing <br> policyholders | $11 \%$ | $0 \%$ | $5 \%$ | $63 \%$ | $21 \%$ |
| Actuarial valuation | $16 \%$ | $11 \%$ | $5 \%$ | $63 \%$ | $5 \%$ |
| Accounting - reporting | $26 \%$ | $5 \%$ | $5 \%$ | $59 \%$ | $5 \%$ |
| Comptroller and treasurer | $26 \%$ | $5 \%$ | $5 \%$ | $59 \%$ | $5 \%$ |
| Legal (regular recurring) | $21 \%$ | $16 \%$ | $16 \%$ | $42 \%$ | $5 \%$ |
| President, CEO, COO budgets | $31 \%$ | $11 \%$ | $21 \%$ | $32 \%$ | $5 \%$ |
| Other senior executives (not in marketing) | $26 \%$ | $16 \%$ | $21 \%$ | $26 \%$ | $11 \%$ |
| Audit fees, regulatory fees | $32 \%$ | $5 \%$ | $16 \%$ | $42 \%$ | $5 \%$ |
| Guarantee association assessments | $42 \%$ | $0 \%$ | $0 \%$ | $32 \%$ | $26 \%$ |
| Public and shareholder relations | $32 \%$ | $11 \%$ | $5 \%$ | $36 \%$ | $16 \%$ |
| Charitable and community expenses | $47 \%$ | $10 \%$ | $0 \%$ | $32 \%$ | $11 \%$ |
| Corporate budgeting | $21 \%$ | $11 \%$ | $5 \%$ | $52 \%$ | $11 \%$ |
| Corporate planning | $32 \%$ | $11 \%$ | $5 \%$ | $41 \%$ | $11 \%$ |


|  | All Companies |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Item | $0 \%$ | Less than <br> $50 \%$ | $50 \%$ to <br> $99 \%$ | $100 \%$ | N/A |
| Field expenses related to servicing <br> policyholders | $17 \%$ | $9 \%$ | $7 \%$ | $50 \%$ | $17 \%$ |
| Actuarial valuation | $15 \%$ | $17 \%$ | $11 \%$ | $53 \%$ | $4 \%$ |
| Accounting - reporting | $26 \%$ | $11 \%$ | $11 \%$ | $48 \%$ | $4 \%$ |
| Comptroller and treasurer | $25 \%$ | $11 \%$ | $9 \%$ | $46 \%$ | $9 \%$ |
| Legal (regular recurring) | $26 \%$ | $19 \%$ | $11 \%$ | $40 \%$ | $4 \%$ |
| President, CEO, COO budgets | $32 \%$ | $19 \%$ | $13 \%$ | $32 \%$ | $4 \%$ |
| Other senior executives (not in marketing) | $26 \%$ | $28 \%$ | $11 \%$ | $29 \%$ | $6 \%$ |
| Audit fees, regulatory fees | $35 \%$ | $9 \%$ | $7 \%$ | $45 \%$ | $4 \%$ |
| Guarantee association assessments | $36 \%$ | $4 \%$ | $4 \%$ | $43 \%$ | $13 \%$ |
| Public and shareholder relations | $33 \%$ | $11 \%$ | $4 \%$ | $35 \%$ | $17 \%$ |
| Charitable and community expenses | $44 \%$ | $11 \%$ | $2 \%$ | $35 \%$ | $8 \%$ |
| Corporate budgeting | $30 \%$ | $11 \%$ | $7 \%$ | $45 \%$ | $7 \%$ |
| Corporate planning | $33 \%$ | $15 \%$ | $4 \%$ | $41 \%$ | $7 \%$ |

9. For UL and FPDA products, should the first year commission be reduced by the ultimate renewal rate in determining the amount of deferred acquisition costs?

## UL (All Companies)

21 of 23 responding companies answered "yes".

FPDA (All Companies)
9 of 20 responding companies answered "yes".
10. Do excess commission deferrals take into account agent termination rates?
$18 \%$ responded "yes". However, $46 \%$ of the respondents indicated that renewal commissions are not vested (All Companies).
11. Do you capitalize the excess first year (teaser) rates of credited interest to FAS97 policyholders?

| Stock-Publicly Traded | All Other | All Companies |
| :--- | :--- | :--- |
| $15 \%$ responded yes (3 of 20) | $28 \%$ responded yes (8 of 29) | $22 \%$ responded yes (11 of 49) |
| $35 \%$ responded no (7 of 20) | $24 \%$ responded no (7 of 29) | $29 \%$ responded no (14 of 49) |
| $50 \%$ responded not applicable (no | $48 \%$ responded not applicable (14 of <br> teaser rates) (10 of 20) | $49 \%$ responded not applicable (24 of <br> ter |

12. For UL products with level or declining COI's, do you set up any unreleased profit/revenue liability to prevent fronting of profits?

| Stock-Publicly Traded | All Other | All Companies |
| :--- | :--- | :--- |
| $35 \%$ responded yes (7 of 20) | $17 \%$ responded yes (5 of 30) | $24 \%$ responded yes (12 of 50) |
| $15 \%$ responded no (3 of 20) | $7 \%$ responded no (2 of 30) | $10 \%$ responded no (5 of 50) |
| $50 \%$ responded not applicable (10 of | $76 \%$ responded not applicable (23 of <br> $30)$ | $66 \%$ responded not applicable (33 of <br> $50)$ |

13. Should implied COI charges, in cases where first year COI charges are zero or very low, be capitalized or go to reduce first year loads?

| Stock-Publicly Traded | All Other | All Companies |
| :--- | :--- | :--- |
| $5 \%$ responded yes (1 of 21) | $0 \%$ responded yes (0 of 29) | $2 \%$ responded yes (1 of 50) |
| $29 \%$ responded no (6 of 21) | $3 \%$ responded no (1 of 29) | $14 \%$ responded no (7 of 50) |
| $66 \%$ responded not applicable (14 of | $97 \%$ responded not applicable (28 of <br> $21)$ | $84 \%$ responded not applicable (42 of <br> $29)$ |

## II. AMORTIZATION OF DAC

1. Do you use actual emerging inforce to amortize FAS60 DAC?

|  | Stock-Publicly Traded | All Companies |
| :--- | :---: | :---: |
| Yes | $90 \%$ | $88 \%$ |
| No | $10 \%$ | $12 \%$ |

2. Over what time period do you amortize FAS60 DAC?

|  | Stock-Publicly Traded | All Companies |
| :--- | :---: | :---: |
| Premium pay period | $50 \%$ | $50 \%$ |
| Less than premium pay period <br> (77 years) | $45 \%$ | $40 \%$ |
| Other | $5 \%$ | $10 \%$ |

3. For FAS60 life products, do you "lock-in" all assumptions at issue in the amortization of $\boldsymbol{D A C}$ ?

|  | Stock-Publicly Traded | All Companies |
| :--- | :---: | :---: |
| Yes | $95 \%$ | $92 \%$ |
| No | $5 \%$ | $8 \%$ |

Comment
In cases where loss recognition does not apply, some companies interpret FAS60 to indicate that lapse rates, if significant, can be unlocked with a resulting set of new DAC and reserve factors.
4. Do you allow gross margins (FAS120) to go negative in the amortization process?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes, but only to the extent <br> there are positive margins <br> remaining at the plan level | $13 \%$ (1 of 8$)$ | $36 \%$ (5 of 14$)$ | $27 \%(6$ of 22$)$ |
| No. Set the negative margin <br> equal to zero | $62 \%(5$ of 8$)$ | $50 \%(7$ of 14$)$ | $55 \%(12$ of 22$)$ |
| Other | $25 \%(2$ of 8$)$ | $14 \%(2$ of 14$)$ | $18 \%(4$ of 22$)$ |

## 5. Do you allow gross GAAP profits (FAS97) to go negative in the amortization process?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes, but only to the extent <br> there are remaining positive <br> margins at the plan level | $45 \%(9$ of 21$)$ | $24 \%(5$ of 21$)$ | $33 \%(14$ of 42$)$ |
| No. Set the negative margin <br> equal to zero | $50 \%(11$ of 21$)$ | $71 \%(15$ of 21$)$ | $62 \%(26$ of 42$)$ |
| Other | $5 \%(1$ of 21$)$ | $5 \%(1$ of 21$)$ | $5 \%(2$ of 42$)$ |

## 6. What discount rate do you use to discount gross GAAP profits (FAS97) and to accrue interest on DAC?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Lock in credited rate at <br> inception | $35 \%(7$ of 20$)$ | $35 \%(8$ of 23$)$ | $35 \%(15$ of 43$)$ |
| Reset to current credited rate | $55 \%(11$ of 20$)$ | $47 \%(11$ of 23$)$ | $51 \%(22$ of 43$)$ |
| Other | $10 \%(2$ of 20$)$ | $18 \%(4$ of 23$)$ | $14 \%(6$ of 43$)$ |

7. What discount rate do you use to discount gross margins (FAS120) and accrue interest on DAC?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Lock in credited rate at <br> inception | $50 \%(6$ of 12$)$ | $39 \%(7$ of 18$)$ | $43 \%(13$ of 30$)$ |
| Reset to current credited rate | $42 \%(5$ of 12$)$ | $39 \%(7$ of 18$)$ | $40 \%(12$ of 30$)$ |
| Other | $8 \%(1$ of 12$)$ | $22 \%(4$ of 18$)$ | $17 \%(5$ of 30$)$ |

8. How often do you unlock for future assumption changes underlying DAC amortization schedules (FAS97, FAS120)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Quarterly | $10 \%(2$ of 20$)$ | $0 \%(0$ of 26$)$ | $4 \%(2$ of 46$)$ |
| Yearly | $40 \%(8$ of 20$)$ | $77 \%(20$ of 26$)$ | $61 \%(28$ of 46$)$ |
| Periodically | $50 \%(10$ of 20$)$ | $23 \%(6$ of 26$)$ | $35 \%(16$ of 46$)$ |

9. How often do you use actual emerging sources of earnings in DAC amortization (FAS97, FAS120)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Monthly | $5 \%(1$ of 19$)$ | $23 \%(6$ of 26$)$ | $16 \%(7$ of 45$)$ |
| Quarterly | $73 \%(14$ of 19$)$ | $42 \%(11$ of 26$)$ | $56 \%(25$ of 45$)$ |
| Semi-Annual | $0 \%(0$ of 19$)$ | $0 \%(0$ of 26$)$ | $0 \%(0$ of 45$)$ |
| Annual | $11 \%(2$ of 19$)$ | $35 \%(9$ of 26$)$ | $24 \%(11$ of 45$)$ |
| Other | $11 \%(2$ of 19$)$ | $0 \%(0$ of 26$)$ | $4 \%(2$ of 45$)$ |

10. How often do you "refresh" the inventory used to project future gross GAAP profits/margins for amortization of $D A C$ purposes?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Quarterly | $30 \%(6$ of 20$)$ | $19 \%(5$ of 26$)$ | $24 \%(11$ of 46$)$ |
| Semi-Annual | $5 \%(1$ of 20$)$ | $4 \%(1$ of 26$)$ | $4 \%(2$ of 46$)$ |
| Annual | $50 \%(10$ of 20$)$ | $62 \%(16$ of 26$)$ | $57 \%(26$ of 46$)$ |
| Other | $15 \%(3$ of 20$)$ | $15 \%(4$ of 26$)$ | $15 \%(7$ of 46$)$ |

11. For deferred annuities without significant mortality risk, what methodology is used to amortize DAC ?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Constant yield method | $11 \%(2$ of 19$)$ | $24 \%(6$ of 25$)$ | $18 \%(8$ of 44$)$ |
| In proportion to gross GAAP <br> profits | $89 \%(17$ of 19$)$ | $72 \%(18$ of 25$)$ | $80 \%(35$ of 44$)$ |
| Other | $0 \%(0$ of 19$)$ | $4 \%(1$ of 25$)$ | $2 \%(1$ of 44$)$ |

12. How is the gross GAAP profit for amortization purposes calculated for products that have a first year bonus interest rate?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Do not have bonus rates | $53 \%(10$ of 19$)$ | $34 \%(9$ of 26$)$ | $42 \%(19$ of 45$)$ |
| Exclude from the gross profits | $16 \%(3$ of 19$)$ | $27 \%(7$ of 26$)$ | $22 \%(10$ of 45$)$ |
| Include in gross profits | $31 \%(6$ of 19$)$ | $31 \%(8$ of 26$)$ | $31 \%(14$ of 45$)$ |
| Other | $0 \%(0$ of 19$)$ | $8 \%(2$ of 26$)$ | $5 \%(2$ of 45$)$ |

13. In the development of future GAAP margins/profits, do you use yield rates based on actual assets backing the reserves (i.e., segmented)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes | $45 \%$ (9 of 20$)$ | $35 \%$ (9 of 26$)$ | $39 \%$ (18 of 46$)$ |
| No (use assumed yield and <br> spread) | $55 \%(11$ of 20$)$ | $65 \%(17$ of 26$)$ | $61 \%(28$ of 46$)$ |

14. In producing gross GAAP margins/profits, do you use the results from a series of future interest rate scenarios?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes | $0 \%(0$ of 20$)$ | $8 \%(2$ of 25$)$ | $5 \%(2$ of 45$)$ |
| No (use level future interest <br> rate scenario) | $90 \%(18$ of 20$)$ | $76 \%(19$ of 25$)$ | $82 \%(37$ of 45$)$ |
| Other | $10 \%(2$ of 20$)$ | $16 \%(4$ of 25$)$ | $13 \%(6$ of 45$)$ |

15. For FAS90/FAS120 products, do you need to keep a separate amortization schedule by year of issue?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Project margins/profits by year <br> of issue and amortize DAC by <br> year of issue | $65 \%(13$ of 20) | $73 \%(19$ of 26) | $69 \%(32$ of 46) |
| Project margins/profits by year <br> of issue for recent issue years <br> and aggregate older blocks and <br> amortize DAC accordingly | $25 \%$ (5 of 20) | $19 \%$ (5 of 26) | $22 \%(10$ of 46) |
| Other | $10 \%(2$ of 20$)$ | $8 \%(2$ of 26$)$ | $9 \%(4$ of 46$)$ |

16. At what level are sources of earnings developed in the amortization of DAC when unlocking for actual emerging mortality experience?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Plan/age/duration | $25 \%$ (5 of 20) | $11 \%$ (3 of 26) | $17 \%(8$ of 46) |
| Plan/duration (all ages <br> combined) | $25 \%(5$ of 20$)$ | $27 \%(7$ of 26$)$ | $26 \%(12$ of 46$)$ |
| Plan (all ages and durations <br> combined) | $0 \%(0$ of 20$)$ | $11 \%(3$ of 26$)$ | $7 \%(3$ of 46$)$ |
| Groups of similar plans by <br> age/duration | $25 \%(5$ of 20$)$ | $15 \%(4$ of 26$)$ | $20 \%(9$ of 46$)$ |
| Groups of similar plans (all <br> ages and durations combined $)$ | $25 \%(5$ of 20$)$ | $28 \%(7$ of 26$)$ | $26 \%(12$ of 46$)$ |
| Other | $0 \%(0$ of 20$)$ | $8 \%(2$ of 26$)$ | $4 \%(2$ of 46$)$ |

17. For new business, what is the level of aggregation used for testing for recoverability?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Plan/issue age basis | $0 \%(0$ of 23$)$ | $10 \%(3$ of 30$)$ | $6 \%(3$ of 53$)$ |
| Plan basis (all ages, sexes and <br> smoker status combined) | $9 \%(2$ of 23$)$ | $20 \%(6$ of 30$)$ | $15 \%(8$ of 53$)$ |
| Product type (UL vs WL vs <br> Term) | $61 \%(14$ of 23$)$ | $33 \%(10$ of 30$)$ | $45 \%(24$ of 53$)$ |
| Line of business (life vs <br> Annuity vs A\&H) | $30 \%(7$ of 23$)$ | $20 \%(6$ of 30$)$ | $24 \%(13$ of 53$)$ |
| Total company (all LOB's <br> combined) | $0 \%(0$ of 23$)$ | $10 \%(3$ of 30$)$ | $6 \%(3$ of 53$)$ |
| Other | $0 \%(0$ of 23$)$ | $7 \%(2$ of 30$)$ | $4 \%(2$ of 53$)$ |

18. For inforce business, what is the level of aggregation used for testing for loss recognition?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Plan/issue age basis | $0 \%(0$ of 22$)$ | $3 \%(1$ of 29$)$ | $2 \%(1$ of 51$)$ |
| Plan basis (all ages, sexes and <br> smoker status combined) | $9 \%(2$ of 22$)$ | $10 \%(3$ of 29$)$ | $10 \%(5$ of 51$)$ |
| Product type (UL vs WL vs <br> Term) | $55 \%(12$ of 22$)$ | $28 \%(8$ of 29$)$ | $39 \%(20$ of 51$)$ |
| Line of business <br> Annuity vs A\&H) | $27 \%(6$ of 22$)$ | $45 \%(13$ of 29$)$ | $37 \%(19$ of 51$)$ |
| Total company | $4.5 \%(1$ of 22$)$ | $7 \%(2$ of 29$)$ | $6 \%(3$ of 51$)$ |
| Other | $4.5 \%(1$ of 22$)$ | $7 \%(2$ of 29$)$ | $6 \%(3$ of 51$)$ |

19. In performing loss recognition testing on inforce blocks, which experience assumptions are considered?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Mortality/morbidity | $74 \%(17$ of 23$)$ | $73 \%(22$ of 30$)$ | $74 \%(39$ of 53$)$ |
| Lapses | $70 \%(16$ of 23$)$ | $80 \%(24$ of 30$)$ | $75 \%(40$ of 53$)$ |
| Yields/spreads | $65 \%(15$ of 23$)$ | $83 \%(25$ of 30$)$ | $75 \%(40$ of 53$)$ |
| Maintenance expenses | $61 \%(14$ of 23$)$ | $77 \%(23$ of 30$)$ | $70 \%(37$ of 53$)$ |
| Overhead expenses | $35 \%(8$ of 23$)$ | $30 \%(9$ of 30$)$ | $32 \%(17$ of 53$)$ |
| Other | $9 \%(2$ of 23$)$ | $0 \%(0$ of 30$)$ | $4 \%(2$ of 53$)$ |

20. In performing loss recognition testing on inforce blocks, which actions/assumptions would you use in performing this test for DAC recoverability?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :---: | :---: | :---: | :---: |
| Include inflation | 64\% (16 of 25) | 50\% (14 of 28) | 56\% (30 of 53) |
| Include inflation but partially offset by assumed growth in inforce | 24\% (6 of 25) | $35 \%$ (10 of 28) | 30\% (16 of 53) |
| If necessary to show recoverability, you would provide for some future mortality improvement | 0\% (0 of 25) | 11\% (3 of 28) | 6\% (3 of 53) |
| You would perform testing under a variety of yield curves using actual assets to reach a conclusion | 12\% (3 of 25) | 0\% (0 of 28) | 6\% (3 of 53) |
| If necessary to show recoverability, you would provide for some rise in future interest rates and spreads given the current yield curves | 0\% (0 of 25) | 4\% (1 of 28) | 2\% (1 of 53) |

## 21. Which of the following management actions would you reflect in loss recognition testing? (Select all that apply)

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Management indicates that a <br> COI rate increase will be <br> implemented in the next 12 <br> months. There are no <br> regulatory issues in the rate <br> increases. | $70 \%$ (16 of 23) | $57 \%$ (17 of 30) | $66 \%(35$ of 53) |
| Management indicates it will <br> raise COI rates several years <br> into the future. You include the | $17 \%$ (4 of 23) | $13 \%(4$ of 30) | $15 \%(8$ of 53) |
| COI increases in your current <br> testing with the increase <br> effective in the indicated future <br> year. |  |  |  |
| Possible rate increases are <br> sufficient to prevent loss <br> recognition. However, <br> management indicates that <br> current and future losses are to <br> be considered period costs as it <br> can get increases if it desires. | $9 \%$ (2 of 23) | $10 \%$ (3 of 30) | $9 \%$ (5 of 53) |
| Interest spreads over recent <br> years are insufficient to <br> recover DAC. Management <br> indicates that the spreads will <br> be increased starting in a few <br> years. You increase the spreads <br> in the testing starting at the <br> distant future date indicated by <br> management. DAC is now <br> recoverable. | $9 \%$ (2 of 23$)$ | $20 \%$ (6 of 30) | $15 \%$ (8 of 53) |

22. Current portfolio interest spreads are sufficient to recover DAC. However, spreads based on the new money rates are not sufficient to recover DAC. There are no other ways to generate additional profits other than spreads. $\boldsymbol{A}$ test is made to measure the declining portfolio rate as inforce assets mature and new cash flows are invested at the current new money rates. DAC is reexamined for loss recognition and DAC is still not fully recoverable. Which of the following actions would you take?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Do not write off DAC since <br> current portfolio rates are <br> sufficient | $21 \%$ (3 of 14) | $22 \%$ (4 of 18$)$ | $22 \%(7$ of 32$)$ |
| Write off DAC based on future <br> portfolio yields reflecting a <br> decline in yield to the current <br> new money rates | $72 \%$ (10 of 14) | $67 \%$ (12 of 18$)$ | $69 \%$ (22 of 32) |
| Retest using a rising new <br> money interest rate scenario <br> which keeps the future <br> portfolio rates higher in <br> support of reducing DAC <br> write-offs | $7 \%(1$ of 14) | $11 \%(2$ of 18$)$ | $9 \%(3$ of 32$)$ |
| Other |  | $0 \%(0$ of 14$)$ | $0 \%(0$ of 18$)$ |

23. Are assets segmented for DAC amortization and loss recognition purposes?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes | $63 \%(12$ of 19$)$ | $39 \%(11$ of 28$)$ | $49 \%(23$ of 47$)$ |
| No | $37 \%(7$ of 19$)$ | $61 \%(17$ of 28$)$ | $51 \%(24$ of 47$)$ |

24. When assets are segmented for GAAP purposes, which of the following applies for FAS97/FAS120 business?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Assets when assigned to a <br> product group stay in that <br> group until maturity or sale | $45 \%$ (9 of 20) | $35 \%$ (9 of 26) | $33 \%$ (15 of 46) |
| Limited amounts of assets are <br> reallocated among plan groups | $35 \%$ (7 of 20) | $23 \%$ (6 of 26) | $28 \%$ (13 of 46) |
| Full reallocations are permitted | $10 \%$ (2 of 20) | $4 \%(1$ of 26) | $7 \%(3$ of 46) |
| Realized capital gains/losses <br> are assigned to the product <br> group where the asset was held <br> at the beginning of the <br> financial reporting period | $40 \%$ (8 of 20) | $12 \%$ (3 of 26) | $24 \%$ (11 of 46) |
| Realized capital gains/losses <br> are assigned to the product <br> group where the asset was held <br> at the time of sale | $45 \%(9$ of 20) | $35 \%(9$ of 26$)$ | $39 \%(18$ of 46$)$ |
| Other |  |  |  |

25. For policy conversions, when would you carry the DAC on the original policy over to the new policy?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| FAS97 Life to FAS97 Life | $9 \%(2$ of 22$)$ | $22 \%(6$ of 27$)$ | $16 \%(8$ of 49$)$ |
| FAS60 Term to FAS60 <br> Permanent | $9 \%(2$ of 22$)$ | $7 \%(2$ of 27$)$ | $8 \%(4$ of 49$)$ |
| FAS60 Permanent to FAS60 <br> Permanent | $14 \%(3$ of 22$)$ | $15 \%(4$ of 27$)$ | $14 \%(7$ of 49$)$ |
| FAS60 Term to FAS60 Term | $14 \%(3$ of 22$)$ | $15 \%(4$ of 27$)$ | $14 \%(7$ of 49$)$ |

## III. BENEFIT RESERVES

1. How often do you perform mortality/morbidity studies which are at a level that would be reasonably sufficient to set or evaluate GAAP assumptions?

|  | Stock-Publicly Traded |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yearly | $60 \%(9$ of 15$)$ | $65 \%(11$ of 17$)$ | $53 \%(9$ of 17$)$ | $67 \%(16$ of 9$)$ |
| Every two years or longer | $33 \%(5$ of 15$)$ | $29 \%(5$ of 17$)$ | $29 \%(5$ of 17$)$ | $0 \%(0$ of 9$)$ |
| No studies | $7 \%(1$ of 15$)$ | $6 \%(1$ of 17$)$ | $18 \%(3$ of 17$)$ | $33 \%(3$ of 9$)$ |


|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yearly | $58 \%(18$ of 31$)$ | $66 \%(25$ of 38$)$ | $54 \%(20$ of 37$)$ | $68 \%(15$ of 22$)$ |
| Every two years or longer | $32 \%(10$ of 31$)$ | $26 \%(10$ of 38$)$ | $32 \%(12$ of 37$)$ | $9 \%(2$ of 22$)$ |
| No studies | $10 \%(3$ of 31$)$ | $8 \%(3$ of 38$)$ | $14 \%(5$ of 37$)$ | $23 \%(5$ of 22$)$ |

2. How do you set your GAAP mortality/morbidity assumptions?

|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Company derived table <br> based on actual experience | $23 \%(7$ of 31$)$ | $26 \%(10$ of 38$)$ | $22 \%(8$ of 37$)$ | $38 \%$ (8 of 21$)$ |
| Industry table adjusted to <br> reflect your experience | $64 \%(20$ of 31$)$ | $63 \%$ (24 of 38$)$ | $67 \%(25$ of 37$)$ | $43 \%$ (9 of 21$)$ |
| All other | $13 \%(4$ of 31$)$ | $11 \%(4$ of 38$)$ | $11 \%(4$ of 37$)$ | $19 \%$ (4 of 21$)$ |

3. How often do you perform lapse studies which would be at a level sufficient to set or evaluate GAAP assumptions?

|  | Stock-Publicly Traded |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yearly | $73 \%(11$ of 15$)$ | $76 \%$ (13 of 17$)$ | $71 \%(12$ of 17$)$ | $89 \%(8$ of 9$)$ |
| Every two years or longer | $20 \%(3$ of 15$)$ | $18 \%(3$ of 17$)$ | $23 \%(4$ of 17$)$ | $0 \%(0$ of 9$)$ |
| No studies | $7 \%(1$ of 15$)$ | $6 \%(1$ of 17$)$ | $6 \%(1$ of 17$)$ | $11 \%(1$ of 9$)$ |


|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yearly | $61 \%$ (19 of 31) | $66 \%(25$ of 38$)$ | $60 \%(22$ of 37$)$ | $81 \%(17$ of 21$)$ |
| Every two years or longer | $26 \%(8$ of 31$)$ | $24 \%(9$ of 38$)$ | $32 \%(12$ of 37$)$ | $10 \%(2$ of 21$)$ |
| No studies | $13 \%(4$ of 31$)$ | $10 \%(4$ of 38$)$ | $8 \%(3$ of 37$)$ | $9 \%(2$ of 21$)$ |

## 4. Do you put in a provision for mortality improvement in setting reserves?

|  | Stock-Publicly Traded |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yes, less than $1 \%$ yearly <br> for a specified time | $6 \%(1$ of 16$)$ | $10 \%(2$ of 20$)$ | $10.5 \%$ (2 of 19$)$ | $9 \%(1$ of 11$)$ |
| Yes, between $1 \%$ and $2 \%$ <br> yearly for a limited time | $0 \%(0$ of 16$)$ | $0 \%(0$ of 20$)$ | $0 \%(0$ of 19$)$ | $0 \%(0$ of 11$)$ |
| No | $88 \%(14$ of 16$)$ | $85 \%(17$ of 20$)$ | $79 \%(15$ of 19$)$ | $73 \%(8$ of 11$)$ |
| Other | $6 \%(1$ of 16$)$ | $5 \%(1$ of 20$)$ | $10.5 \%(2$ of 19$)$ | $18 \%(2$ of 11$)$ |


|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yes, less than 1\% yearly <br> for a specified time | $6 \%(2$ of 33$)$ | $7 \%(3$ of 41$)$ | $10.5 \%(4$ of 38$)$ | $9 \%(2$ of 23$)$ |
| Yes, between $1 \%$ and $2 \%$ <br> yearly for a limited time | $3 \%(1$ of 33$)$ | $2.5 \%(1$ of 41$)$ | $0 \%(0$ of 38$)$ | $0 \%(0$ of 23$)$ |
| No | $88 \%(29$ of 33$)$ | $88 \%(36$ of 41$)$ | $79 \%(30$ of 38$)$ | $78 \%(18$ of 23$)$ |
| Other | $3 \%(1$ of 33$)$ | $2.5 \%(1$ of 41$)$ | $10.5 \%(4$ of 38$)$ | $13 \%(3$ of 23$)$ |

## 5. Do you assume any future increase or decrease in interest earnings rates before PAD's for GAAP?

|  | Stock-Publicly Traded |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| No, assume interest <br> remains level | $85 \%(11$ of 13) | $87 \%(13$ of 15$)$ | $83 \%(10$ of 12$)$ | $100 \%(5$ of 5$)$ |
| Yes, assume some increase | $0 \%(0$ of 13) | $0 \%(0$ of 15$)$ | $0 \%(0$ of 12$)$ | $0 \%(0$ of 5$)$ |
| Yes, assume some <br> decrease | $15 \%(2$ of 13$)$ | $13 \%(2$ of 15$)$ | $17 \%(2$ of 12$)$ | $0 \%(0$ of 5$)$ |


|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| No, assume interest <br> remains level | $76 \%(22$ of 29$)$ | $75 \%(27$ of 36$)$ | $83 \%(24$ of 29$)$ | $81 \%(13$ of 16$)$ |
| Yes, assume some increase | $0 \%(0$ of 29$)$ | $0 \%(0$ of 36$)$ | $3 \%(1$ of 29$)$ | $6 \%(1$ of 16$)$ |
| Yes, assume some <br> decrease | $24 \%(7$ of 29$)$ | $25 \%(9$ of 36$)$ | $14 \%(4$ of 29$)$ | $13 \%(2$ of 16$)$ |

6. Do you provide for inflation in the GAAP maintenance expense assumptions?

|  | All Companies |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Traditional Life - <br> Permanent Non-Par | Traditional Life - <br> Term Non-Par | UL | VUL |
| Yes | $45 \%(14$ of 31$)$ | $46 \%(18$ of 39$)$ | $54 \%(19$ of 35$)$ | $43 \%(9$ of 21$)$ |
| No | $45 \%(14$ of 31$)$ | $46 \%(18$ of 39$)$ | $34 \%(12$ of 35$)$ | $38 \%(8$ of 21$)$ |
| Reduction in maintenance <br> expenses | $3 \%(1$ of 31$)$ | $3 \%(1$ of 39$)$ | $6 \%(2$ of 35$)$ | $9.5 \%(2$ of 21$)$ |
| Other | $7 \%(2$ of 31$)$ | $5 \%(2$ of 39$)$ | $6 \%(2$ of 35$)$ | $9.5 \%(2$ of 21$)$ |

7. For FAS60 products, how long has it been since a new GAAP era of assumptions was introduced for FAS60 products?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Less than one year | $33 \%(7$ of 21$)$ | $30 \%(8$ of 27$)$ | $31 \%(15$ of 48$)$ |
| Between 1 to 2 years | $24 \%(5$ of 21$)$ | $30 \%(8$ of 27$)$ | $27 \%(13$ of 48$)$ |
| More than 2 years but less than <br> 3 years | $10 \%(2$ of 21$)$ | $15 \%(4$ of 27$)$ | $13 \%(6$ of 48$)$ |
| More than 3 years but less than <br> 4 years | $14 \%(3$ of 21$)$ | $4 \%(1$ of 27$)$ | $8 \%(4$ of 48$)$ |
| 4 or more years | $19 \%(4$ of 21$)$ | $21 \%(6$ of 27$)$ | $21 \%(10$ of 48$)$ |

## 8. Within the last four years, what was the need for a new FAS60 GAAP era?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Interest only | $13 \%(2$ of 15$)$ | $6 \%(1$ of 18$)$ | $9 \%(3$ of 33$)$ |
| Mortality/morbidity only | $33 \%(5$ of 15$)$ | $17 \%(3$ of 18$)$ | $24 \%(8$ of 33$)$ |
| Lapses only | $0 \%(0$ of 15$)$ | $0 \%(0$ of 18$)$ | $0 \%(0$ of 33$)$ |
| Maintenance expense only | $0 \%(0$ of 15$)$ | $0 \%(0$ of 18$)$ | $0 \%(0$ of 33$)$ |
| Combination | $54 \%(8$ of 15$)$ | $77 \%(14$ of 18$)$ | $67 \%(22$ of 33$)$ |

## 9. For indeterminate premium plans that are classified as FAS60, what best describes the practice for setting provisions for adverse deviation?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| No provisions | $0 \%(0$ of 20$)$ | $0 \%(0$ of 28$)$ | $0 \%(0$ of 48$)$ |
| Lower than another <br> comparable guaranteed <br> premium product | $5 \%(1$ of 20$)$ | $14 \%(4$ of 28$)$ | $11 \%(5$ of 48$)$ |
| Same as of guaranteed <br> premium products | $75 \%(15$ of 20$)$ | $39 \%(11$ of 28$)$ | $54 \%(26$ of 48$)$ |
| Other | $5 \%(1$ of 20$)$ | $4 \%(1$ of 28$)$ | $4 \%(2$ of 48$)$ |
| Not Applicable | $15 \%(3$ of 20$)$ | $43 \%(12$ of 28$)$ | $31 \%(15$ of 48$)$ |

10. For UL products with inforce guarantees, do you allow the account value to go negative for reporting purposes?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Not Applicable | $36.5 \%$ (8 of 22) | $45 \%$ (12 of 27$)$ | $41 \%$ (20 of 49) |
| Yes, aggregate with other <br> positive amounts at the plan <br> level subject to a minimum of <br> zero | $27 \%$ (6 of 22) | $7 \%$ (2 of 27$)$ | $16 \%(8$ of 49$)$ |
| No, set equal to zero at the <br> policyholder level | $36.5 \%$ (8 of 22) | $48 \%(13$ of 27$)$ | $43 \%(21$ of 49) |

11. For FAS97 products with positive future gross GAAP profits followed by negative future GAAP profits, what is your practice in funding for these losses?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Fund the future losses as a <br> level percent of positive <br> margins (at the plan level) | $41 \%$ (7 of 17$)$ | $9 \%(2$ of 23$)$ | $23 \%$ (9 of 40$)$ |
| Group the plan with other <br> plans with positive margins | $6 \%$ (1 of 17$)$ | $61 \%(14$ of 23$)$ | $37 \%(15$ of 40$)$ |
| Other | $53 \%(9$ of 17$)$ | $30 \%(7$ of 23$)$ | $40 \%(16$ of 40$)$ |

12. For FAS97 products with future interest bonuses or retroactive benefits on specified dates, how are extra reserves established?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Build up reserves as a level <br> percentage of profit margins <br> prior to bonus date at the plan <br> level | $47 \%$ (9 of 19) | $26 \%$ (5 of 19) | $37 \%(14$ of 38$)$ |
| Build up reserves as a level <br> percentage of profit margins <br> prior to bonus date including <br> plans without such benefits | $11 \%(2$ of 19$)$ | $16 \%(3$ of 19$)$ | $13 \%(5$ of 38$)$ |
| Other | $42 \%(8$ of 19$)$ | $58 \%(11$ of 19$)$ | $50 \%(19$ of 38$)$ |

## IV. PURCHASE GAAP

1. Does PGAAP apply to your company?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| No | $22 \%(5$ of 23$)$ | $54 \%(17$ of 31$)$ | $41 \%(22$ of 54$)$ |
| Yes, acquired entity | $43 \%(10$ of 23$)$ | $23 \%(7$ of 31$)$ | $31 \%(17$ of 54$)$ |
| Yes, acquiring entity | $35 \%(8$ of 23$)$ | $23 \%(7$ of 31$)$ | $28 \%(15$ of 54$)$ |

## 2. For PGAAP reserves on FAS60 business, which method best describes your company practice?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Deferred Valuation Premium <br> method (DVP) | $42 \%$ (8 of 19) | $24 \%$ (3 of 13$)$ | $34 \%(11$ of 32$)$ |
| Deferred Initial Reserve <br> method (DIR) | $37 \%$ (7 of 19) | $38 \%(5$ of 13$)$ | $38 \%(12$ of 32$)$ |
| No FAS60 business or <br> insignificant amount with <br> GAAP set equal to statutory | $21 \%$ (4 of 19) | $38 \%(5$ of 13$)$ | $28 \%(9$ of 32$)$ |
| Other | $0 \%(0$ of 19$)$ | $0 \%(0$ of 13$)$ | $0 \%(0$ of 32$)$ |

## 3. Under the DVP method, how are valuation net premiums determined?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| A single percent rate of the <br> gross premium was selected | $100 \%$ (4 of 4) | $0 \%(0$ of 7$)$ | $36 \%(4$ of 11$)$ |
| A single percent rate at the <br> product level | $0 \%(0$ of 4$)$ | $29 \%(2$ of 7$)$ | $18 \%(2$ of 11$)$ |
| A derived method which <br> produces a rate at the plan/age <br> cell basis (i.e. use historical <br> GAAP methodology but use | $0 \%(0$ of 4$)$ | $71 \%(5$ of 7$)$ | $46 \%(5$ of 11$)$ |
| PGAAP assumptions from <br> issue date to produce current <br> GAAP reserves |  |  |  |

## 4. Under the DIR method, how are initial reserves defined?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Set PGAAP reserve equal to <br> pre-purchase GAAP reserve | $43 \%(3$ of 7$)$ | $0 \%(0$ of 4$)$ | $27 \%(3$ of 11$)$ |
| Set PGAAP reserve equal to <br> statutory reserve | $14 \%(1$ of 7$)$ | $0 \%(0$ of 4$)$ | $9 \%(1$ of 11$)$ |
| Set PGAAP reserve equal to a <br> percentage of the statutory <br> reserves | $29 \%(2$ of 7$)$ | $50 \%(2$ of 4$)$ | $37 \%(4$ of 11$)$ |
| Other | $14 \%(1$ of 7$)$ | $50 \%(2$ of 4$)$ | $27 \%(3$ of 11$)$ |

## 5. For FAS60 products, what portion of the gross premium was used to develop the PVP

 or Value of Business Acquired (VOBA)?|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Applied a risk discount rate to <br> the present value to all <br> remaining gross premium after <br> providing for benefits and <br> expenses | $67 \%$ (10 of 15) | $37 \%$ (3 of 8) | $57 \%(13$ of 23) |
| Applied a risk discount rate to <br> all remaining gross premium <br> after providing for benefits, <br> expenses, and a reasonable | $13 \%(2$ of 15) | $50 \%(4$ of 8) | $26 \%(6$ of 23) |
| level of profits thus allowing a <br> percentage of the premium to <br> flow directly to earnings | $20 \%(3$ of 15) | $13 \%(1$ of 8$)$ |  |
| Other |  | $17 \%(4$ of 23$)$ |  |

6. For FAS97 products, how was PVP/VOBA developed?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Applied a risk discount rate to <br> $100 \%$ of the best estimate <br> future PGAAP gross GAAP <br> profits | $60 \%$ (9 of 15) | $80 \%(8$ of 10$)$ | $68 \%(17$ of 25$)$ |
| Applied a risk discount rate to <br> less than $100 \%$ of the best <br> estimate future PGAAP gross <br> GAAP profits | $7 \%$ (1 of 15) | $10 \%(1$ of 10$)$ | $8 \%(2$ of 25$)$ |
| Used the pretax statutory <br> appraisal with an adjustment <br> for the difference in statutory <br> and GAAP reserves | $20 \%(3$ of 15$)$ | $10 \%(1$ of 10$)$ | $16 \%(4$ of 25$)$ |
| Other |  |  | $0 \%(0$ of 10$)$ |

7. In certain cases, PGAAP accounting permits a restatement of the initial PGAAP
balance sheet to allow more time to value assets and liabilities. This window, depending upon the situation may be for up to twelve months. Under what situations would you develop revised reserves, PVP, and resulting good will?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :---: | :---: | :---: | :---: |
| Assumptions studies were not completed in time to create the initial PGAAP reserves and PVP for the first quarterly financial reporting after the purchase. Rough assumption estimates based on limited available data in combination with industry data had to be used. Studies were later completed based on experience prior to acquisition (no emerging experience after acquisition was used) and new reserves and PVP were more accurately calculated and restated for the following reporting quarter | 100\% (16 of 16) | 92\% (11 of 12) | 96\% (27 of 28) |
| Rough models had to be quickly assembled to create the PGAAP reserves and PVP in order to have values for the opening PGAAP balance sheet and for the first quarterly financial reporting. Over the next quarter, more complete and better models were developed to more accurately calculate reserves and PVP. These new values are used and the initial Goodwill is restated | 100\% (16 of 16) | 75\% (9 of 12) | 89\% (25 of 28) |

8. In developing reserves and PVP, which of the following expenses (other than commission) applies to GAAP?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :---: | :---: | :---: | :---: |
| PGAAP expenses are to be the same as under historical GAAP (HGAAP). | $47 \%$ (8 of 17) | 31\% (4 of 13) | 40\% (12 of 30) |
| Only pure maintenance expenses are used (no allocation of corporate overhead and indirect support departments) | 23\% (4 of 17) | 8\% (1 of 13) | 17\% (5 of 30) |
| Pure maintenance with a share of allocated indirect support functions | 6\% (1 of 17) | 15\% (2 of 13) | 10\% (3 of 30) |
| Pure maintenance with a share of indirect support functions and corporate overhead | 18\% (3 of 17) | 38\% (5 of 13) | 27\% (8 of 30) |
| Other | 6\% (1 of 17) | 8\% (1 of 13) | 6\% (2 of 30) |

9. Should excess maintenance and operating expense, which are to be present for some limited time after a purchase, be taken into consideration in setting reserves and PVP?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes | $35 \%(6$ of 17$)$ | $42 \%(5$ of 12$)$ | $38 \%(11$ of 29$)$ |
| No | $65 \%(11$ of 17$)$ | $58 \%(7$ of 12$)$ | $62 \%(18$ of 29$)$ |

10. Should any portions of the historical unearned revenue liability be carried over to the PGAAP balance sheets?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| None | $100 \%(10$ of 10$)$ | $33 \%(2$ of 6$)$ | $75 \%(12$ of 16$)$ |
| $100 \%$ | $0 \%(0$ of 10$)$ | $50 \%(3$ of 6$)$ | $19 \%(3$ of 16$)$ |
| Some portion | $0 \%(0$ of 10$)$ | $17 \%(1$ of 6$)$ | $6 \%(1$ of 16$)$ |

11. For FAS60 products, should margins for adverse deviation be included in the reserves and PVP?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Yes | $88 \%(15$ of 17$)$ | $90 \%(9$ of 10$)$ | $89 \%(24$ of 27$)$ |
| No | $12 \%(2$ of 17$)$ | $10 \%(1$ of 10$)$ | $11 \%(3$ of 27$)$ |

12. What time period is used to amortize good will (current practice)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| 10 years or less | $6.25 \%(1$ of 16$)$ | $15 \%(2$ of 13$)$ | $10 \%(3$ of 29$)$ |
| 15 years | $6.25 \%(1$ of 16$)$ | $8 \%(1$ of 13$)$ | $7 \%(2$ of 29$)$ |
| 20 years | $31.25 \%(5$ of 16$)$ | $31 \%(4$ of 13$)$ | $31 \%(9$ of 29$)$ |
| 25 years | $0 \%(0$ of 16$)$ | $15 \%(2$ of 13$)$ | $7 \%(2$ of 29$)$ |
| 30 years | $25 \%(4$ of 16$)$ | $23 \%(3$ of 13$)$ | $24 \%(7$ of 29$)$ |
| 40 years | $25 \%(4$ of 16$)$ | $0 \%(0$ of 13$)$ | $14 \%(4$ of 29$)$ |
| Other | $6.25 \%(1$ of 16$)$ | $8 \%(1$ of 13$)$ | $7 \%(2$ of 29$)$ |

13. How is "good will" tested for loss recognition (indicate all that apply)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Based on value of new <br> business (undiscounted future <br> profits) | $0 \%(0$ of 15$)$ | $17 \%(2$ of 12$)$ | $7 \%(2$ of 27$)$ |
| Based on value of new <br> business (discounted future <br> profits) | $20 \%$ (3 of 15$)$ | $8 \%(1$ of 12$)$ | $15 \%$ (4 of 27) |
| Based on value of new <br> business plus excess profit <br> margins on the purchase block | $0 \%(0$ of 15$)$ | $8 \%(1$ of 12$)$ | $4 \%(1$ of 27$)$ |
| Other | $7 \%(1$ of 15$)$ | $0 \%(0$ of 12$)$ | $4 \%(1$ of 27$)$ |
| Not tested | $73 \%(11$ of 15$)$ | $67 \%(8$ of 12$)$ | $70 \%(19$ of 27$)$ |

14. For loss recognition purposes, which statements apply (line of business used below is broadly defined to be operations split by types of products, such as individual versus group, individual life versus individual health versus individual annuities, etc.)?

| Situation | Stock-Publicly Traded | All Other | All Companies |
| :---: | :---: | :---: | :---: |
| PVP, for a subsidiary is tested for loss recognition at the line of business level without regard to any excess margins from DAC or from any other subsidiaries acquired during the same purchase transaction | $40 \%$ (7 of 17) | 34\% (3 of 9) | $37 \%$ (10 of 26) |
| PVP, for a subsidiary, is tested for loss recognition for all lines of business combined without regard to any excess margins from DAC or from any other subsidiaries | 24\% (4 of 17) | 22\% ( 2 of 9) | 23\% (6 of 26) |
| PVP, for a subsidiary, is tested for loss recognition using excess margins from DAC on issues after purchase (at the line of business level) | 12\% (2 of 17) | 11\% (1 of 9) | 12\% (3 of 26) |
| PVP, for a subsidiary, is tested for loss recognition using excess margin from DAC (all lines combined) | 0\% (0 of 17) | 0\% (0 of 9) | 0\% (0 of 26) |
| PVP is tested for loss recognition in the aggregate for all subsidiaries combined within a given purchased group of companies (i.e., multiple companies purchased in a single transaction from a seller) | 6\% (1 of 17) | 0\% (0 of 9) | 4\% (1 of 26) |
| PVP is tested for recoverability in the aggregate where more than one set of purchased groups of companies is owned by a holding company | 0\% (0 of 17) | 0\% (0 of 9) | 0\% (0 of 26) |
| PVP is tested for loss recognition at the line of business level for all companies combined within a single purchase | 12\% (2 of 17) | 11\% (1 of 9) | 12\% (3 of 26) |
| Other | 6\% (1 of 17) | 22\% (2 of 9) | 12\% (3 of 26) |

## 15. Have you ever restated the initial reserves and PVP after crossing over the first quarter of reporting after a purchase and within 12 months (no errors involved)?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| No | $65 \%(11$ of 17$)$ | $50 \%(6$ of 12$)$ | $59 \%(17$ of 29$)$ |
| Yes | $35 \%(6$ of 17$)$ | $50 \%(6$ of 12$)$ | $41 \%(12$ of 29$)$ |

## V. FAS 115

FAS 115 requires that certain marketable securities be "marked to fair value" each accounting period. This results in unrealized holding gains and losses (UHGL) that impact shareholders equity and possibly other balance sheet entries. One such adjustment involves DAC where under a portion of a company's UHGLs are used to adjust the DAC asset account ("shadow" DAC). For the questions below, " K " is defined to be the amortization rate applied to gross GAAP margins to produce amortization of DAC before the shadow adjustment.

## 1. Which of the following apply regarding your company's calculation of a "shadow" DAC on FAS97 and FAS120 products?

|  | Stock-Publicly Traded | All Other | All Companies |
| :---: | :---: | :---: | :---: |
| Apply the "K" factor to the net UHGL's expressed as a straight percentage of the UHGL's for each accounting period | $59 \%$ (10 of 17) | 91\% (20 of 22) | 75\% (30 of 40) |
| Recalculate " K " from issue ( $\mathrm{K}^{\prime}$ ) and apply to UHGL's with future interest yields reflecting the hypothetical sale of the assets and reflecting a lower future profit spread | 29\% (5 of 17) | 0\% (0 of 22) | 12.5\% (5 of 40) |
| Recalculate " $K$ " from issue ( $\mathrm{K}^{\prime}$ ) and apply to UHGL's with future interest yields reflecting the hypothetical sale of the assets and maintaining pre-sale profit spreads without dropping below statutory minimums | 12\% (2 of 17) | 9\% (2 of 22) | 10\% (4 of 40) |
| Recalculate " K " from issue but use some other approach | 0\% (0 of 17) | 0\% (0 of 22) | 2.5\% (1 of 40) |

2. For FAS60 products where the current market yield under FAS115 would create a yield rate at a level where there would be a need for loss recognition, should a shadow adjustment to DAC or reserves be created?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| FAS115 shadow adjustments <br> do not apply to FAS60 <br> products | $61 \%(11$ of 18$)$ | $88 \%(21$ of 24$)$ | $76 \%(32$ of 42$)$ |
| Adjustments do apply | $33 \%(6$ of 18$)$ | $4 \%(1$ of 24$)$ | $17 \%(7$ of 42$)$ |
| Other | $6 \%(1$ of 18$)$ | $8 \%(2$ of 24$)$ | $7 \%(3$ of 42$)$ |

3. How do I allocate the UHGL to determine the "shadow" DAC adjustments?

|  | Stock-Publicly Traded | All Other | All Companies |
| :--- | :---: | :---: | :---: |
| Assets are segmented by <br> product group and the UHGL <br> is allocated directly to that <br> group | $56 \%(9$ of 16$)$ | $47.5 \%(10$ of 21$)$ | $51 \%(19$ of 37$)$ |
| Assets are not segmented and <br> the UHGL is allocated based <br> on a pro-rated approach | $25 \%(4$ of 16$)$ | $47.5 \%(10$ of 21$)$ | $38 \%(14$ of 37$)$ |
| Other | $19 \%(3$ of 16$)$ | $5 \%(1$ of 21$)$ | $11 \%(4$ of 37$)$ |

